Abstract 318: Core Body Temperature Reduction as a Function of Ice-Cold Saline Infusion for the Induction of Hypothermia
Introduction: The infusion of ice-cold saline (ICS) is often employed for the initiation of therapeutic hypothermia, and many protocols suggest an infusion of up to 30cc/kg in order to achieve one commonly used target temperature range of 32-34 degrees Celcius. We sought to determine if there was any association between ICS volume and core temperature reduction.
Methods: We analyzed a convenience sample of out-of-hospital cardiac arrest patients for whom therapeutic hypothermia was being inducted via pressurized ICS infusion and for whom core body temperature was being monitored via an esophageal temperature probe.
Results: Esophageal core temperature data was available for 287 patients. The average patient received 1,136ml (SD 472mL) of ICS via pressure infusion. The average core body temperature upon ED arrival was within the identified target range for all patients (33.2oC, SD 2.3 oC). Among patients who received <500ml (n=29), 501-1000ml (n=165), 1001-1500ml (n=45) and >1500ml (n=48), average core body temperature achieved target range for all groups (33.34 oC, 33.25 oC, 33.5 oC and 32.87 oC, respectively) though there were patients in each group whose core body temperature was either above or below the target range (SD = 2.64 oC, 2.26 oC, 1.34 oC and 2.11 oC, respectively). No correlation was found between the reduction in core body temperature and the infused volume of ICS (ΔT = -0.95 oC±1.52, -1.51 oC ±1.93, -1.40 oC±1.38, -1.45 oC±1.21, respectively).
Conclusions: Though perhaps tempered by the disproportionate number of patients in one group, our data would suggest that the relative reduction in and resulting final core body temperature are not a function of the infused volume for patient undergoing the induction of therapeutic hypothermia via ICS infusion. Therefore, if targeted temperature therapy is of clinically important, continuous core temperature monitoring during the induction of cooling is essential to ensure target acquisition.
Author Disclosures: J. Freese: None. T. Slesinger: None. J. Rabrich: None. M. Menegus: None. R. Silverman: None. N. Keller: None. J. Dillworth: None. D. Ben-Eli: None. D. Isaacs: None. G. Asaeda: None. P. Lai: None. D. Prezant: None.
- © 2014 by American Heart Association, Inc.